Literature DB >> 35451597

[Lipoprotein apheresis : State of the art and case report of the longest HELP treatment worldwide].

Adrienn Tünnemann-Tarr1, Julius Ludwig Katzmann2, Joachim Thiery3, Ulrich Laufs2.   

Abstract

Lipoprotein apheresis is an extracorporeal procedure for the treatment of patients with homozygous familial hypercholesterolemia, patients with severe treatment-resistant hypercholesterolemia and patients with lipoprotein(a) hypercholesterolemia, who show progressive atherosclerotic cardiovascular disease despite optimal treatment. This article reports on the historical developments of the procedures, the most frequently used methods for apheresis as well as the data situation on efficacy and tolerability. Randomized prospective studies on clinical outcomes are not available. Furthermore, the article reports on a patient with homozygous familial hypercholesterolemia and 34 years of treatment with heparin-induced extracorporeal low-density lipoprotein (LDL) precipitation (HELP) apheresis, the longest treatment of this kind worldwide. A second patient with combined heterozygous familial hypercholesterolemia and 31 years of liposorber and HELP apheresis is also described. The observational studies and the case reports demonstrate the safety and long-term tolerability of the procedure.
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Atherosclerosis; Familial hypercholesterolaemia; Heparin-induced extracorporeal LDL precipitation; LDL cholesterol; Lipoprotein(a)

Mesh:

Substances:

Year:  2022        PMID: 35451597     DOI: 10.1007/s00059-022-05115-9

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  30 in total

1.  Effects of different lipoprotein apheresis methods on serum protein levels.

Authors:  U Julius; G Siegert; H Kostka; U Schatz; B Hohenstein
Journal:  Atheroscler Suppl       Date:  2015-05       Impact factor: 3.235

Review 2.  Toward an international consensus-Integrating lipoprotein apheresis and new lipid-lowering drugs.

Authors:  Claudia Stefanutti; Ulrich Julius; Gerald F Watts; Mariko Harada-Shiba; Maria Cossu; Volker J Schettler; Giustina De Silvestro; Handrean Soran; Jeanine Roeters Van Lennep; Livia Pisciotta; Hans U Klör; Kurt Widhalm; Patrick M Moriarty
Journal:  J Clin Lipidol       Date:  2017-04-25       Impact factor: 4.766

3.  Why an apheresis center should offer more than one lipoprotein apheresis method.

Authors:  Ulrich Julius; Sabine Fischer; Ulrike Schatz; Jens Passauer; Stefan Bornstein
Journal:  Ther Apher Dial       Date:  2012-10-12       Impact factor: 1.762

4.  Safety aspects of lipidapheresis using DALI and MONET - Multicenter observational study.

Authors:  Justyna Kozik-Jaromin; Eberhard Röseler; Franz Heigl; Ralf Spitthöver; Jens Ringel; Gerd Schmitz; Rainer Heinzler; Nadim Abdul-Rahman; Frank Leistikow; Frido Himmelsbach; Volker Schettler; Ingrid Uhlenbusch-Körwer; Wolfgang Ramlow
Journal:  Atheroscler Suppl       Date:  2017-11       Impact factor: 3.235

5.  Efficacy of lipid reduction with DALI and MONET.

Authors:  Wolfgang Ramlow; Eberhard Röseler; Franz Heigl; Ralf Spitthöver; Jens Ringel; Gerd Schmitz; Rainer Heinzler; Nadim Abdul-Rahman; Frank Leistikow; Frido Himmelsbach; Volker Schettler; Jenny Pham; Justyna Kozik-Jaromin
Journal:  Atheroscler Suppl       Date:  2017-06-01       Impact factor: 3.235

6.  Efficacy of different low-density lipoprotein apheresis methods.

Authors:  K G Parhofer; H C Geiss; P Schwandt
Journal:  Ther Apher       Date:  2000-10

Review 7.  Epidemiology of familial hypercholesterolaemia: Community and clinical.

Authors:  Antonio J Vallejo-Vaz; Kausik K Ray
Journal:  Atherosclerosis       Date:  2018-10       Impact factor: 5.162

8.  Intraindividual comparison of two extracorporeal LDL apheresis methods: lipidfiltration and HELP.

Authors:  U Julius; W Metzler; J Pietzsch; T Fassbender; R Klingel
Journal:  Int J Artif Organs       Date:  2002-12       Impact factor: 1.595

9.  Effects of two whole blood systems (DALI and Liposorber D) for LDL apheresis on lipids and cardiovascular risk markers in severe hypercholesterolemia.

Authors:  Carsten Otto; Jutta Berster; Bärbel Otto; Klaus G Parhofer
Journal:  J Clin Apher       Date:  2007       Impact factor: 2.821

10.  2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

Authors:  François Mach; Colin Baigent; Alberico L Catapano; Konstantinos C Koskinas; Manuela Casula; Lina Badimon; M John Chapman; Guy G De Backer; Victoria Delgado; Brian A Ference; Ian M Graham; Alison Halliday; Ulf Landmesser; Borislava Mihaylova; Terje R Pedersen; Gabriele Riccardi; Dimitrios J Richter; Marc S Sabatine; Marja-Riitta Taskinen; Lale Tokgozoglu; Olov Wiklund
Journal:  Eur Heart J       Date:  2020-01-01       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.